Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE
Phase of Trial: Phase IV
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors AbbVie
- 16 Nov 2017 Planned End Date changed from 20 Jun 2019 to 2 May 2019.
- 16 Nov 2017 Planned primary completion date changed from 20 Jun 2019 to 2 May 2019.
- 14 Sep 2017 Planned End Date changed from 2 May 2019 to 20 Jun 2019.